Interaksi Losartan

Losartan (Cozaar), golongan penghambat reseptor angiotensin II (ARB), memiliki 173 interaksi terdokumentasi dalam label FDA dan lembar fakta yang kami indeks: 13 mayor, 132 moderat, 21 minor, dan 7 dengan label yang melaporkan tidak ada interaksi bermakna. Setiap entri di bawah ini mengutip kalimat yang mendasarinya. Halaman obat ini adalah titik awal, bukan putusan untuk situasi Anda.

Losartan adalah penghambat reseptor angiotensin II (ARB) yang dijual sebagai Cozaar dan secara luas sebagai obat generik. Obat ini menghambat sinyal hormon yang menyempitkan pembuluh darah, yang menurunkan tekanan darah. Obat ini disetujui untuk tekanan darah tinggi pada orang dewasa dan anak di atas 6 tahun, untuk menurunkan risiko stroke pada orang dengan tekanan darah tinggi dan pembesaran otot jantung, dan untuk penyakit ginjal pada diabetes tipe 2. Obat ini tersedia sebagai tablet 25, 50, dan 100 mg, biasanya diminum sekali sehari, dengan atau tanpa makanan.

Interaksi dari label

Interaksi mayor (13)

  • AliskirenantihipertensiMayor

    For coadministration with aliskiren in patients with diabetes. (label Losartan, Kontraindikasi)

  • Amlodipin dan benazeprilpenghambat kanal kalsium dihidropiridinMayor

    Do not coadminister aliskiren with angiotensin receptor blockers (ARBs), angiotensin-converting enzyme (ACE) inhibitors, including amlodipine and benazepril hydrochloride capsules in patients with diabetes. (label Amlodipin dan benazepril, Kontraindikasi)

  • Benazeprilpenghambat ACEMayor

    Do not coadminister aliskiren with angiotensin receptor blockers, ACE inhibitors, including Lotensin in patients with diabetes [see Drug Interactions (7.4) ] . (label Benazepril, Kontraindikasi)

  • Do not coadminister aliskiren with angiotensin receptor blockers, ACE inhibitors, including Lotensin HCT in patients with diabetes. (label Benazepril dan hidroklorotiazid, Kontraindikasi)

  • EptifibatidantiplateletMayor

    …of active abnormal bleeding within the previous 30 days Severe hypertension (systolic blood pressure >200 mm Hg or diastolic blood pressure >110 mm Hg) not adequately controlled on antihypertensive therapy Major surgery within the preceding 6 weeks History of stroke within 30 days or any history of hemorrhagic stroke Current or planned administration of another… (label Eptifibatid, Kontraindikasi)

  • Feri sitratpengikat fosfatMayor

    …administered concomitantly with Ferric Citrate Tablets Amlodipine Aspirin Atorvastatin Calcitriol Clopidogrel Digoxin Diltiazem Doxercalciferol Enalapril Fluvastatin Glimepiride Levofloxacin Losartan Metoprolol Pravastatin Propranolol Sitagliptin Warfarin Oral drugs that have to be separated from Ferric Citrate Tablets and meals Dosing Recommendations Doxycycline Take at… (label Feri sitrat, Interaksi obat)

  • KaliumVitamin dan mineralMayor

    Obat-obat ini mengurangi ekskresi kalium; menambahkan suplemen kalium atau garam pengganti dapat menyebabkan hiperkalemia, yang memengaruhi irama jantung. (NIH Office of Dietary Supplements, Potassium)

  • KlozapinantipsikotikMayor

    Use CLOZARIL cautiously in patients with cardiovascular or cerebrovascular disease or conditions predisposing to hypotension (e.g., dehydration, use of antihypertensive medications) [see Dosage and Administration ( 2.2 , 2.6 ), Warnings and Precautions ( 5.2 )]. (label Klozapin, Peringatan kotak hitam)

  • Lisinoprilpenghambat ACEMayor

    Patients receiving the combination of losartan and lisinopril did not obtain any additional benefit compared to monotherapy for the combined endpoint of decline in GFR, end stage renal disease, or death, but experienced an increased incidence of hyperkalemia and acute kidney injury compared with the monotherapy group. (label Losartan, Interaksi obat)

  • Patients receiving the combination of losartan and lisinopril did not obtain any additional benefit compared to monotherapy for the combined endpoint of decline in GFR, end stage renal disease, or death, but experienced an increased incidence of hyperkalemia and acute kidney injury compared with the monotherapy group. (label Losartan, Interaksi obat)

  • Metolazondiuretik tiazidMayor

    Other Antihypertensive Drugs When metolazone tablets, USP, are used with other antihypertensive drugs, particular care must be taken to avoid excessive reduction of blood pressure, especially during initial therapy. (label Metolazon, Peringatan)

  • MinoksidilvasodilatorMayor

    Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (label Minoksidil, Peringatan kotak hitam)

  • Tadalafilpenghambat PDE5Mayor

    …coadministration of an alpha-blocker and CIALIS for the treatment of BPH has not been adequately studied, and due to the potential vasodilatory effects of combined use resulting in blood pressure lowering, the combination of CIALIS and alpha-blockers is not recommended for the treatment of BPH. [see Dosage and Administration ( 2.7 ), Drug Interactions ( 7.1 ),… (label Tadalafil, Peringatan dan perhatian)

Interaksi moderat (132)

  • Alfuzosinpenyekat alfaModerat

    Postural hypotension/syncope: Care should be taken in patients with symptomatic hypotension or who have had a hypotensive response to other medications or are concomitantly treated with antihypertensive medication or nitrates ( 5.1 ) (label Alfuzosin, Peringatan dan perhatian)

  • Amiloriddiuretik hemat kaliumModerat

    Hypotension in Volume- or Salt-Depleted Patients In patients with an activated renin-angiotensin system, such as volume- or salt-depleted patients (e.g., those being treated with high doses of diuretics), symptomatic hypotension may occur after initiation of treatment with COZAAR. (label Losartan, Peringatan dan perhatian)

  • AripiprazolantipsikotikModerat

    Antihypertensive Drugs Due to its alpha-adrenergic antagonism, aripiprazole has the potential to enhance the effect of certain antihypertensive agents. (label Aripiprazol, Interaksi obat)

  • Armodafinilstimulan SSPModerat

    There was also a slightly greater proportion of patients on NUVIGIL requiring new or increased use of antihypertensive medications (2.9%) compared to patients on placebo (1.8%). (label Armodafinil, Peringatan dan perhatian)

  • Asam etakrinatdiuretik loopModerat

    Hypotension in Volume- or Salt-Depleted Patients In patients with an activated renin-angiotensin system, such as volume- or salt-depleted patients (e.g., those being treated with high doses of diuretics), symptomatic hypotension may occur after initiation of treatment with COZAAR. (label Losartan, Peringatan dan perhatian)

  • Asam mefenamatOAINSModerat

    NSAIDs: Increased risk of renal impairment and reduced diuretic, natriuretic, and antihypertensive effects. (label Losartan, Interaksi obat)

  • AsenapinantipsikotikModerat

    Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (elderly patients, patients with dehydration, hypovolemia, concomitant treatment with antihypertensive medications, patients with known cardiovascular disease (history of myocardial infarction or ischemic heart disease, heart failure, or conduction abnormalities), and patients… (label Asenapin, Peringatan dan perhatian)

  • Asetazolamidpenghambat karbonat anhidraseModerat

    Hypotension in Volume- or Salt-Depleted Patients In patients with an activated renin-angiotensin system, such as volume- or salt-depleted patients (e.g., those being treated with high doses of diuretics), symptomatic hypotension may occur after initiation of treatment with COZAAR. (label Losartan, Peringatan dan perhatian)

  • AspirinOAINSModerat

    NSAIDs: Increased risk of renal impairment and reduced diuretic, natriuretic, and antihypertensive effects. (label Losartan, Interaksi obat)

  • Aspirin dan dipiridamolantiplateletModerat

    NSAIDs: Increased risk of renal impairment and reduced diuretic, natriuretic, and antihypertensive effects. (label Losartan, Interaksi obat)

  • Atenololpenyekat betaModerat

    Because of its relative beta 1 selectivity, however, TENORMIN may be used with caution in patients with bronchospastic disease who do not respond to, or cannot tolerate, other antihypertensive treatment. (label Atenolol, Peringatan)

  • Atenolol dan klortalidonpenyekat betaModerat

    Hypotension in Volume- or Salt-Depleted Patients In patients with an activated renin-angiotensin system, such as volume- or salt-depleted patients (e.g., those being treated with high doses of diuretics), symptomatic hypotension may occur after initiation of treatment with COZAAR. (label Losartan, Peringatan dan perhatian)

  • Atomoksetinpenghambat ambilan kembali norepinefrinModerat

    Antihypertensive Drugs Prevention or Management Increase the frequency of monitoring blood pressure and adjust atomoxetine oral solution dosage as clinically appropriate. (label Atomoksetin, Interaksi obat)

  • Avanafilpenghambat PDE5Moderat

    • Use of avanafil with alpha-blockers, other antihypertensives, or substantial amounts of alcohol (greater than 3 units) may lead to hypotension ( 2.3 , 5.6 , 5.7 ) (label Avanafil, Peringatan dan perhatian)

  • Benzfetaminstimulan SSPModerat

    Amphetamines may decrease the hypotensive effect of antihypertensives. (label Benzfetamin, Interaksi obat)

  • Bisoprololpenyekat betaModerat

    Because of its relative beta 1 -selectivity, however, BISOPROLOL FUMARATE may be used with caution in patients with bronchospastic disease who do not respond to, or who cannot tolerate other antihypertensive treatment. (label Bisoprolol, Peringatan)

  • Hypotension in Volume- or Salt-Depleted Patients In patients with an activated renin-angiotensin system, such as volume- or salt-depleted patients (e.g., those being treated with high doses of diuretics), symptomatic hypotension may occur after initiation of treatment with COZAAR. (label Losartan, Peringatan dan perhatian)

  • BortezomibModerat

    Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (label Bortezomib, Peringatan dan perhatian)

  • BrekspiprazolantipsikotikModerat

    Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, concomitant treatment with antihypertensive medication), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and… (label Brekspiprazol, Peringatan dan perhatian)

  • Brimonidinagonis alfa-adrenergikModerat

    Antihypertensives/Cardiac Glycosides Because brimonidine tartrate ophthalmic solution 0.1% and 0.15% may reduce blood pressure, caution in using drugs such as antihypertensives and/or cardiac glycosides with brimonidine tartrate ophthalmic solution 0.1% and 0.15% is advised. (label Brimonidin, Interaksi obat)

  • Brimonidin dan timololagonis alfa-adrenergikModerat

    Antihypertensives/Cardiac Glycosides Because brimonidine tartrate/timolol maleate ophthalmic solution may reduce blood pressure, caution in using drugs such as antihypertensives and/or cardiac glycosides with brimonidine tartrate/timolol maleate ophthalmic solution is advised. (label Brimonidin dan timolol, Interaksi obat)

  • Central Nervous System (CNS) depressants Antihistamines have additive effects with alcohol and other CNS depressants (hypnotics, sedatives, tranquilizers, antianxiety agents, etc.). Antihypertensive drugs Sympathomimetic may reduce the effects of antihypertensive drugs. (label Bromfeniramin, pseudoefedrin, dan dekstrometorfan, Interaksi obat)

  • Bromokriptinagonis dopaminModerat

    Use caution in patients taking antihypertensive medications. (label Bromokriptin, Peringatan dan perhatian)

  • Bumetaniddiuretik loopModerat

    Hypotension in Volume- or Salt-Depleted Patients In patients with an activated renin-angiotensin system, such as volume- or salt-depleted patients (e.g., those being treated with high doses of diuretics), symptomatic hypotension may occur after initiation of treatment with COZAAR. (label Losartan, Peringatan dan perhatian)

  • NSAIDs: Increased risk of renal impairment and reduced diuretic, natriuretic, and antihypertensive effects. (label Losartan, Interaksi obat)

  • NSAIDs: Increased risk of renal impairment and reduced diuretic, natriuretic, and antihypertensive effects. (label Losartan, Interaksi obat)

  • Deksmetilfenidatstimulan SSPModerat

    • Antihypertensive Drugs: Monitor blood pressure. (label Deksmetilfenidat, Interaksi obat)

  • Dietilpropionstimulan SSPModerat

    The pressor effects of diethylpropion and those of other drugs may be additive when the drugs are used concomitantly; conversely, diethylpropion may interfere with antihypertensive drugs (i.e., guanethidine, a-methyldopa). (label Dietilpropion, Interaksi obat)

  • DiflunisalOAINSModerat

    NSAIDs: Increased risk of renal impairment and reduced diuretic, natriuretic, and antihypertensive effects. (label Losartan, Interaksi obat)

  • DiklofenakOAINSModerat

    NSAIDs: Increased risk of renal impairment and reduced diuretic, natriuretic, and antihypertensive effects. (label Losartan, Interaksi obat)

  • NSAIDs: Increased risk of renal impairment and reduced diuretic, natriuretic, and antihypertensive effects. (label Losartan, Interaksi obat)

  • Drospirenon dan etinilestradiolkontrasepsi oralModerat

    Medications that may increase serum potassium concentration include ACE inhibitors, angiotensin-II receptor antagonists, potassium-sparing diuretics, potassium supplementation, heparin, aldosterone antagonists, and NSAIDS. (label Drospirenon dan etinilestradiol, Peringatan dan perhatian)

  • DuloksetinSNRIModerat

    The risk of BP decreases may be greater in patients taking concomitant medications that induce orthostatic hypotension (such as antihypertensives) or are potent CYP1A2 inhibitors [see Drug Interactions ( 7.1 )] and in patients taking duloxetine delayed-release capsules at doses above 60 mg daily. (label Duloksetin, Peringatan dan perhatian)

  • Enalaprilpenghambat ACEModerat

    Dual Blockade of the Renin-Angiotensin System (RAS) Dual blockade of the RAS with angiotensin receptor blockers, ACE inhibitors, or aliskiren is associated with increased risks of hypotension, syncope, hyperkalemia, and changes in renal function (including acute renal failure) compared to monotherapy. (label Losartan, Interaksi obat)

  • Enalapril dan hidroklorotiazidpenghambat ACEModerat

    Hypotension in Volume- or Salt-Depleted Patients In patients with an activated renin-angiotensin system, such as volume- or salt-depleted patients (e.g., those being treated with high doses of diuretics), symptomatic hypotension may occur after initiation of treatment with COZAAR. (label Losartan, Peringatan dan perhatian)

  • Enalaprilatpenghambat ACEModerat

    Dual Blockade of the Renin-Angiotensin System (RAS) Dual blockade of the RAS with angiotensin receptor blockers, ACE inhibitors, or aliskiren is associated with increased risks of hypotension, syncope, hyperkalemia, and changes in renal function (including acute renal failure) compared to monotherapy. (label Losartan, Interaksi obat)

  • EpinefrinsimpatomimetikModerat

    Epinephrine may antagonize the neuronal blockade produced by guanethidine resulting in decreased antihypertensive effect and requiring increased dosage of the latter. (label Epinefrin, Interaksi obat)

  • Eplerenonantagonis aldosteronModerat

    Hypotension in Volume- or Salt-Depleted Patients In patients with an activated renin-angiotensin system, such as volume- or salt-depleted patients (e.g., those being treated with high doses of diuretics), symptomatic hypotension may occur after initiation of treatment with COZAAR. (label Losartan, Peringatan dan perhatian)

  • Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (label Epoetin alfa, Peringatan dan perhatian)

  • Epoprostenolanalog prostaglandinModerat

    Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (label Epoprostenol, Interaksi obat)

  • Esmololpenyekat betaModerat

    Antihypertensive agents clonidine, guanfacine, or moxonidine: Beta blockers also increase the risk of clonidine-, guanfacine-, or moxonidine-withdrawal rebound hypertension. (label Esmolol, Interaksi obat)

  • EtodolakOAINSModerat

    NSAIDs: Increased risk of renal impairment and reduced diuretic, natriuretic, and antihypertensive effects. (label Losartan, Interaksi obat)

  • Fenelzinpenghambat MAOModerat

    …hydrochloride desipramine hydrochloride imipramine hydrochloride doxepin carbamazepine cyclobenzaprine HCl amoxapine maprotiline HCl trimipramine maleate protriptyline HCl mirtazapine Phenelzine sulfate should be used with caution in combination with antihypertensive drugs, including thiazide diuretics and β-blockers, since exaggerated hypotensive effects may result. (label Fenelzin, Peringatan)

  • FenoprofenOAINSModerat

    NSAIDs: Increased risk of renal impairment and reduced diuretic, natriuretic, and antihypertensive effects. (label Losartan, Interaksi obat)

  • Flukonazolantijamur azolModerat

    Fluconazole, an inhibitor of cytochrome P450 2C9, decreased the AUC of the active metabolite by approximately 40%, but increased the AUC of losartan by approximately 70% following multiple doses. (label Losartan, Interaksi obat)

  • FlurbiprofenOAINSModerat

    NSAIDs: Increased risk of renal impairment and reduced diuretic, natriuretic, and antihypertensive effects. (label Losartan, Interaksi obat)

  • Fosinoprilpenghambat ACEModerat

    Dual Blockade of the Renin-Angiotensin System (RAS) Dual blockade of the RAS with angiotensin receptor blockers, ACE inhibitors, or aliskiren is associated with increased risks of hypotension, syncope, hyperkalemia, and changes in renal function (including acute renal failure) compared to monotherapy. (label Losartan, Interaksi obat)

  • Fosinopril dan hidroklorotiazidpenghambat ACEModerat

    Hypotension in Volume- or Salt-Depleted Patients In patients with an activated renin-angiotensin system, such as volume- or salt-depleted patients (e.g., those being treated with high doses of diuretics), symptomatic hypotension may occur after initiation of treatment with COZAAR. (label Losartan, Peringatan dan perhatian)

  • Furosemiddiuretik loopModerat

    Hypotension in Volume- or Salt-Depleted Patients In patients with an activated renin-angiotensin system, such as volume- or salt-depleted patients (e.g., those being treated with high doses of diuretics), symptomatic hypotension may occur after initiation of treatment with COZAAR. (label Losartan, Peringatan dan perhatian)

  • Hidroklorotiaziddiuretik tiazidModerat

    Hypotension in Volume- or Salt-Depleted Patients In patients with an activated renin-angiotensin system, such as volume- or salt-depleted patients (e.g., those being treated with high doses of diuretics), symptomatic hypotension may occur after initiation of treatment with COZAAR. (label Losartan, Peringatan dan perhatian)

  • NSAIDs: Increased risk of renal impairment and reduced diuretic, natriuretic, and antihypertensive effects. (label Losartan, Interaksi obat)

  • IbuprofenOAINSModerat

    NSAIDs: Increased risk of renal impairment and reduced diuretic, natriuretic, and antihypertensive effects. (label Losartan, Interaksi obat)

  • NSAIDs: Increased risk of renal impairment and reduced diuretic, natriuretic, and antihypertensive effects. (label Losartan, Interaksi obat)

  • IloperidonantipsikotikModerat

    Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, and concomitant treatment with antihypertensive medications), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and… (label Iloperidon, Peringatan dan perhatian)

  • Indapamiddiuretik tiazidModerat

    Hypotension in Volume- or Salt-Depleted Patients In patients with an activated renin-angiotensin system, such as volume- or salt-depleted patients (e.g., those being treated with high doses of diuretics), symptomatic hypotension may occur after initiation of treatment with COZAAR. (label Losartan, Peringatan dan perhatian)

  • IndometasinOAINSModerat

    NSAIDs: Increased risk of renal impairment and reduced diuretic, natriuretic, and antihypertensive effects. (label Losartan, Interaksi obat)

  • Irbesartan dan hidroklorotiazidpenghambat reseptor angiotensin II (ARB)Moderat

    Hypotension in Volume- or Salt-Depleted Patients In patients with an activated renin-angiotensin system, such as volume- or salt-depleted patients (e.g., those being treated with high doses of diuretics), symptomatic hypotension may occur after initiation of treatment with COZAAR. (label Losartan, Peringatan dan perhatian)

  • Kandesartan dan hidroklorotiazidpenghambat reseptor angiotensin II (ARB)Moderat

    Hypotension in Volume- or Salt-Depleted Patients In patients with an activated renin-angiotensin system, such as volume- or salt-depleted patients (e.g., those being treated with high doses of diuretics), symptomatic hypotension may occur after initiation of treatment with COZAAR. (label Losartan, Peringatan dan perhatian)

  • Kaptoprilpenghambat ACEModerat

    Dual Blockade of the Renin-Angiotensin System (RAS) Dual blockade of the RAS with angiotensin receptor blockers, ACE inhibitors, or aliskiren is associated with increased risks of hypotension, syncope, hyperkalemia, and changes in renal function (including acute renal failure) compared to monotherapy. (label Losartan, Interaksi obat)

  • KarbidopaModerat

    Symptomatic postural hypotension has occurred when carbidopa, given with levodopa or carbidopa-levodopa combination products, was added to the treatment of a patient receiving antihypertensive drugs. (label Karbidopa, Interaksi obat)

  • Karbidopa dan levodopaobat dopaminergikModerat

    Antihypertensive drugs: May cause symptomatic postural hypotension. (label Karbidopa dan levodopa, Interaksi obat)

  • Karbidopa, levodopa, dan entakaponobat dopaminergikModerat

    Antihypertensive Agents Symptomatic postural hypotension has occurred when carbidopa/levodopa was added to the treatment of patients receiving antihypertensive drugs. (label Karbidopa, levodopa, dan entakapon, Interaksi obat)

  • KariprazinantipsikotikModerat

    Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, and concomitant treatment with antihypertensive medications), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and… (label Kariprazin, Peringatan dan perhatian)

  • Karvedilolpenyekat betaModerat

    COREG may be used with caution, however, in patients who do not respond to, or cannot tolerate, other antihypertensive agents. (label Karvedilol, Peringatan dan perhatian)

  • KetoprofenOAINSModerat

    NSAIDs: Increased risk of renal impairment and reduced diuretic, natriuretic, and antihypertensive effects. (label Losartan, Interaksi obat)

  • KetorolakOAINSModerat

    NSAIDs: Increased risk of renal impairment and reduced diuretic, natriuretic, and antihypertensive effects. (label Losartan, Interaksi obat)

  • Klorotiaziddiuretik tiazidModerat

    Hypotension in Volume- or Salt-Depleted Patients In patients with an activated renin-angiotensin system, such as volume- or salt-depleted patients (e.g., those being treated with high doses of diuretics), symptomatic hypotension may occur after initiation of treatment with COZAAR. (label Losartan, Peringatan dan perhatian)

  • Klortalidondiuretik tiazidModerat

    Hypotension in Volume- or Salt-Depleted Patients In patients with an activated renin-angiotensin system, such as volume- or salt-depleted patients (e.g., those being treated with high doses of diuretics), symptomatic hypotension may occur after initiation of treatment with COZAAR. (label Losartan, Peringatan dan perhatian)

  • KuetiapinantipsikotikModerat

    Quetiapine should be used with particular caution in patients with known cardiovascular disease (history of myocardial infarction or ischemic heart disease, heart failure, or conduction abnormalities), cerebrovascular disease, or conditions which would predispose patients to hypotension (dehydration, hypovolemia, and treatment with antihypertensive medications). (label Kuetiapin, Peringatan dan perhatian)

  • Kuinaprilpenghambat ACEModerat

    Dual Blockade of the Renin-Angiotensin System (RAS) Dual blockade of the RAS with angiotensin receptor blockers, ACE inhibitors, or aliskiren is associated with increased risks of hypotension, syncope, hyperkalemia, and changes in renal function (including acute renal failure) compared to monotherapy. (label Losartan, Interaksi obat)

  • Kuinapril dan hidroklorotiazidpenghambat ACEModerat

    Hypotension in Volume- or Salt-Depleted Patients In patients with an activated renin-angiotensin system, such as volume- or salt-depleted patients (e.g., those being treated with high doses of diuretics), symptomatic hypotension may occur after initiation of treatment with COZAAR. (label Losartan, Peringatan dan perhatian)

  • Litiumobat serotonergikModerat

    Lithium: Risk of lithium toxicity. (label Losartan, Interaksi obat)

  • Losartan dan hidroklorotiazidpenghambat reseptor angiotensin II (ARB)Moderat

    Hypotension in Volume- or Salt-Depleted Patients In patients with an activated renin-angiotensin system, such as volume- or salt-depleted patients (e.g., those being treated with high doses of diuretics), symptomatic hypotension may occur after initiation of treatment with COZAAR. (label Losartan, Peringatan dan perhatian)

  • LumateperonantipsikotikModerat

    Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, and concomitant treatment with antihypertensive drugs), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and patients… (label Lumateperon, Peringatan dan perhatian)

  • LurasidonantipsikotikModerat

    Patients at increased risk of these adverse reactions or at increased risk of developing complications from hypotension include those with dehydration, hypovolemia, treatment with antihypertensive medication, history of cardiovascular disease (e.g., heart failure, myocardial infarction, ischemia, or conduction abnormalities), history of cerebrovascular disease,… (label Lurasidon, Peringatan dan perhatian)

  • MekamilaminantihipertensiModerat

    The action of Mecamylamine HCl may be potentiated by anesthesia, other antihypertensive drugs and alcohol. (label Mekamilamin, Interaksi obat)

  • MeloksikamOAINSModerat

    NSAIDs: Increased risk of renal impairment and reduced diuretic, natriuretic, and antihypertensive effects. (label Losartan, Interaksi obat)

  • Metilfenidatstimulan SSPModerat

    Antihypertensive Drugs: Monitor blood pressure. (label Metilfenidat, Interaksi obat)

  • Hypotension in Volume- or Salt-Depleted Patients In patients with an activated renin-angiotensin system, such as volume- or salt-depleted patients (e.g., those being treated with high doses of diuretics), symptomatic hypotension may occur after initiation of treatment with COZAAR. (label Losartan, Peringatan dan perhatian)

  • MirtazapinantidepresanModerat

    REMERON/REMERONSolTab should be used with caution in patients with known cardiovascular or cerebrovascular disease that could be exacerbated by hypotension (history of myocardial infarction, angina, or ischemic stroke) and conditions that would predispose patients to hypotension (dehydration, hypovolemia, and treatment with antihypertensive medication). (label Mirtazapin, Peringatan dan perhatian)

  • Modafinilstimulan SSPModerat

    However, a retrospective analysis of the use of antihypertensive medication in these studies showed that a greater proportion of patients on PROVIGIL required new or increased use of antihypertensive medications (2.4%) compared to patients on placebo (0.7%). (label Modafinil, Peringatan dan perhatian)

  • Moeksiprilpenghambat ACEModerat

    Dual Blockade of the Renin-Angiotensin System (RAS) Dual blockade of the RAS with angiotensin receptor blockers, ACE inhibitors, or aliskiren is associated with increased risks of hypotension, syncope, hyperkalemia, and changes in renal function (including acute renal failure) compared to monotherapy. (label Losartan, Interaksi obat)

  • NabumetonOAINSModerat

    NSAIDs: Increased risk of renal impairment and reduced diuretic, natriuretic, and antihypertensive effects. (label Losartan, Interaksi obat)

  • NaproksenOAINSModerat

    NSAIDs: Increased risk of renal impairment and reduced diuretic, natriuretic, and antihypertensive effects. (label Losartan, Interaksi obat)

  • NSAIDs: Increased risk of renal impairment and reduced diuretic, natriuretic, and antihypertensive effects. (label Losartan, Interaksi obat)

  • NiasinModerat

    Antihypertensive Therapy Niacin may potentiate the effects of ganglionic blocking agents and vasoactive drugs resulting in postural hypotension. (label Niasin, Interaksi obat)

  • Nimodipinpenghambat kanal kalsium dihidropiridinModerat

    Blood Pressure Lowering Drugs Nimodipine may increase the blood pressure lowering effect of concomitantly administered anti-hypertensives such as diuretics, beta-blockers, ACE inhibitors, angiotensin receptor blockers, other calcium channel blockers, α-adrenergic blockers, PDE5 inhibitors, and α-methyldopa. (label Nimodipin, Interaksi obat)

  • NitrogliserinnitratModerat

    Antihypertensives: Possible additive hypotensive effects. (label Nitrogliserin, Interaksi obat)

  • OksaprozinOAINSModerat

    NSAIDs: Increased risk of renal impairment and reduced diuretic, natriuretic, and antihypertensive effects. (label Losartan, Interaksi obat)

  • OlanzapinantipsikotikModerat

    …of myocardial infarction or ischemia, heart failure, or conduction abnormalities), cerebrovascular disease, and conditions which would predispose patients to hypotension (dehydration, hypovolemia, and treatment with antihypertensive medications) where the occurrence of syncope, or hypotension and/or bradycardia might put the patient at increased medical risk. (label Olanzapin, Peringatan dan perhatian)

  • Olanzapin dan fluoksetinantipsikotikModerat

    …and fluoxetine capsules should be used with particular caution in patients with known cardiovascular disease (history of myocardial infarction or ischemia, heart failure, or conduction abnormalities), cerebrovascular disease, or conditions that would predispose patients to hypotension (dehydration, hypovolemia, and treatment with antihypertensive medications). (label Olanzapin dan fluoksetin, Peringatan dan perhatian)

  • Olmesartan dan hidroklorotiazidpenghambat reseptor angiotensin II (ARB)Moderat

    Hypotension in Volume- or Salt-Depleted Patients In patients with an activated renin-angiotensin system, such as volume- or salt-depleted patients (e.g., those being treated with high doses of diuretics), symptomatic hypotension may occur after initiation of treatment with COZAAR. (label Losartan, Peringatan dan perhatian)

  • Olmesartan, amlodipin, dan hidroklorotiazidpenghambat reseptor angiotensin II (ARB)Moderat

    Hypotension in Volume- or Salt-Depleted Patients In patients with an activated renin-angiotensin system, such as volume- or salt-depleted patients (e.g., those being treated with high doses of diuretics), symptomatic hypotension may occur after initiation of treatment with COZAAR. (label Losartan, Peringatan dan perhatian)

  • NSAIDs: Increased risk of renal impairment and reduced diuretic, natriuretic, and antihypertensive effects. (label Losartan, Interaksi obat)

  • PaliperidonantipsikotikModerat

    Use ERZOFRI with caution in patients with known cardiovascular disease (e.g., heart failure, history of myocardial infarction or ischemia, conduction abnormalities), cerebrovascular disease, or conditions that predispose the patient to hypotension (e.g., dehydration, hypovolemia, and treatment with antihypertensive medications). (label Paliperidon, Peringatan dan perhatian)

  • NSAIDs: Increased risk of renal impairment and reduced diuretic, natriuretic, and antihypertensive effects. (label Losartan, Interaksi obat)

  • PazopanibModerat

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (label Pazopanib, Peringatan dan perhatian)

  • PentoksifilinmetilxantinModerat

    Small decreases in blood pressure have been observed in some patients treated with pentoxifylline extended-release tablets; periodic systemic blood pressure monitoring is recommended for patients receiving concomitant antihypertensive therapy. (label Pentoksifilin, Interaksi obat)

  • Perindoprilpenghambat ACEModerat

    Dual Blockade of the Renin-Angiotensin System (RAS) Dual blockade of the RAS with angiotensin receptor blockers, ACE inhibitors, or aliskiren is associated with increased risks of hypotension, syncope, hyperkalemia, and changes in renal function (including acute renal failure) compared to monotherapy. (label Losartan, Interaksi obat)

  • PiroksikamOAINSModerat

    NSAIDs: Increased risk of renal impairment and reduced diuretic, natriuretic, and antihypertensive effects. (label Losartan, Interaksi obat)

  • Prazosinpenyekat alfaModerat

    Syncopal episodes have usually occurred within 30 to 90 minutes of the initial dose of the drug; occasionally, they have been reported in association with rapid dosage increases or the introduction of another antihypertensive drug into the regimen of a patient taking high doses of prazosin hydrochloride capsules. (label Prazosin, Peringatan)

  • Ramiprilpenghambat ACEModerat

    Dual Blockade of the Renin-Angiotensin System (RAS) Dual blockade of the RAS with angiotensin receptor blockers, ACE inhibitors, or aliskiren is associated with increased risks of hypotension, syncope, hyperkalemia, and changes in renal function (including acute renal failure) compared to monotherapy. (label Losartan, Interaksi obat)

  • RifampisinantibiotikModerat

    However, rifampin has been shown to decrease the AUC of losartan and its active metabolite by 30% and 40%, respectively. (label Losartan, Interaksi obat)

  • RiosiguatvasodilatorModerat

    Consider the potential for symptomatic hypotension or ischemia in patients with hypovolemia, severe left ventricular outflow obstruction, resting hypotension, autonomic dysfunction, or concomitant treatment with antihypertensives or strong CYP and P-gp/BCRP inhibitors [see Drug Interactions (7.2) and Clinical Pharmacology (12.3) ] . (label Riosiguat, Peringatan dan perhatian)

  • RisperidonantipsikotikModerat

    Clinically significant hypotension has been observed with concomitant use of oral RISPERDAL and antihypertensive medication. (label Risperidon, Peringatan dan perhatian)

  • SalsalatOAINSModerat

    NSAIDs: Increased risk of renal impairment and reduced diuretic, natriuretic, and antihypertensive effects. (label Losartan, Interaksi obat)

  • SelekoksibOAINSModerat

    NSAIDs: Increased risk of renal impairment and reduced diuretic, natriuretic, and antihypertensive effects. (label Losartan, Interaksi obat)

  • Siklobenzaprinpelemas ototModerat

    …concomitant use of TONMYA with: MAO inhibitors may be life-threatening [see Contraindications (4) ] , Alcohol, barbiturates, and other CNS depressants may increase the risk of adverse reactions associated with these drugs, Tramadol may increase the seizure risk, Guanethidine or other similar acting drugs may block the antihypertensive action of these drugs. (label Siklobenzaprin, Interaksi obat)

  • SiklosporinimunosupresanModerat

    Caution is also required when cyclosporine is coadministered with potassium sparing drugs (e.g., angiotensin converting enzyme inhibitors, angiotensin II receptor antagonists), potassium-containing drugs as well as in patients on a potassium rich diet. (label Siklosporin, Interaksi obat)

  • Sildenafilpenghambat PDE5Moderat

    Caution is advised when SILDENAFIL ORAL FILM is co-administered with alpha-blockers or antihypertensives. (label Sildenafil, Peringatan dan perhatian)

  • Silodosinpenyekat alfaModerat

    However, patients in the Phase 3 clinical studies taking concomitant antihypertensive medications with silodosin capsules did not experience a significant increase in the incidence of syncope, dizziness, or orthostasis. (label Silodosin, Peringatan dan perhatian)

  • SorafenibModerat

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (label Sorafenib, Peringatan dan perhatian)

  • Spironolaktonantagonis aldosteronModerat

    Hypotension in Volume- or Salt-Depleted Patients In patients with an activated renin-angiotensin system, such as volume- or salt-depleted patients (e.g., those being treated with high doses of diuretics), symptomatic hypotension may occur after initiation of treatment with COZAAR. (label Losartan, Peringatan dan perhatian)

  • Spironolakton dan hidroklorotiazidantagonis aldosteronModerat

    Hypotension in Volume- or Salt-Depleted Patients In patients with an activated renin-angiotensin system, such as volume- or salt-depleted patients (e.g., those being treated with high doses of diuretics), symptomatic hypotension may occur after initiation of treatment with COZAAR. (label Losartan, Peringatan dan perhatian)

  • SulindakOAINSModerat

    NSAIDs: Increased risk of renal impairment and reduced diuretic, natriuretic, and antihypertensive effects. (label Losartan, Interaksi obat)

  • NSAIDs: Increased risk of renal impairment and reduced diuretic, natriuretic, and antihypertensive effects. (label Losartan, Interaksi obat)

  • SunitinibModerat

    Initiate and/or adjust antihypertensive therapy as appropriate. (label Sunitinib, Peringatan dan perhatian)

  • TakrolimusimunosupresanModerat

    • Hypertension: May require antihypertensive therapy; monitor relevant drug interactions. (label Takrolimus, Peringatan dan perhatian)

  • Telmisartan dan hidroklorotiazidpenghambat reseptor angiotensin II (ARB)Moderat

    Hypotension in Volume- or Salt-Depleted Patients In patients with an activated renin-angiotensin system, such as volume- or salt-depleted patients (e.g., those being treated with high doses of diuretics), symptomatic hypotension may occur after initiation of treatment with COZAAR. (label Losartan, Peringatan dan perhatian)

  • Terazosinpenyekat alfaModerat

    Risk of Hypotension with Concomitant Use of Other Antihypertensive Agents and Phospodiesterase Type 5 Inhibitors (PDE5-I): Concomitant administration of TEZRULY with antihypertensives or phosphodiesterase-5 (PDE-5) inhibitors can result in additive blood pressure lowering effects and symptomatic hypotension (5.3). (label Terazosin, Peringatan dan perhatian)

  • TestosteronandrogenModerat

    In patients with hypertension on antihypertensive therapy, TLANDO increased the mean systolic/diastolic BP by 4.8/1.6 mm Hg from baseline. [see Adverse Reactions ( 6.1 )] . (label Testosteron, Peringatan dan perhatian)

  • TolmetinOAINSModerat

    NSAIDs: Increased risk of renal impairment and reduced diuretic, natriuretic, and antihypertensive effects. (label Losartan, Interaksi obat)

  • TolvaptanModerat

    Monitor serum potassium during concomitant therapy with ( 7.2 ): Angiotensin receptor blockers Angiotensin converting enzyme inhibitors Potassium sparing diuretics 7.1 CYP3A Inhibitors and Inducers Strong CYP3A Inhibitors Tolvaptan's AUC was 5.4 times as large and C max was 3.5 times as large after co-administration of tolvaptan and 200 mg ketoconazole [see Warnings… (label Tolvaptan, Interaksi obat)

  • Torasemiddiuretik loopModerat

    Hypotension in Volume- or Salt-Depleted Patients In patients with an activated renin-angiotensin system, such as volume- or salt-depleted patients (e.g., those being treated with high doses of diuretics), symptomatic hypotension may occur after initiation of treatment with COZAAR. (label Losartan, Peringatan dan perhatian)

  • Trandolaprilpenghambat ACEModerat

    Dual Blockade of the Renin-Angiotensin System (RAS) Dual blockade of the RAS with angiotensin receptor blockers, ACE inhibitors, or aliskiren is associated with increased risks of hypotension, syncope, hyperkalemia, and changes in renal function (including acute renal failure) compared to monotherapy. (label Losartan, Interaksi obat)

  • TrazodonantidepresanModerat

    Concomitant use with an antihypertensive may require a reduction in the dose of the antihypertensive drug. (label Trazodon, Peringatan dan perhatian)

  • Triamterendiuretik hemat kaliumModerat

    Hypotension in Volume- or Salt-Depleted Patients In patients with an activated renin-angiotensin system, such as volume- or salt-depleted patients (e.g., those being treated with high doses of diuretics), symptomatic hypotension may occur after initiation of treatment with COZAAR. (label Losartan, Peringatan dan perhatian)

  • Triamteren dan hidroklorotiaziddiuretik hemat kaliumModerat

    Hypotension in Volume- or Salt-Depleted Patients In patients with an activated renin-angiotensin system, such as volume- or salt-depleted patients (e.g., those being treated with high doses of diuretics), symptomatic hypotension may occur after initiation of treatment with COZAAR. (label Losartan, Peringatan dan perhatian)

  • Valsartan dan hidroklorotiazidpenghambat reseptor angiotensin II (ARB)Moderat

    Hypotension in Volume- or Salt-Depleted Patients In patients with an activated renin-angiotensin system, such as volume- or salt-depleted patients (e.g., those being treated with high doses of diuretics), symptomatic hypotension may occur after initiation of treatment with COZAAR. (label Losartan, Peringatan dan perhatian)

  • Vardenafilpenghambat PDE5Moderat

    Vardenafil hydrochloride tablets can potentiate the hypotensive effects of nitrates, alpha- blockers, and antihypertensives. (label Vardenafil, Interaksi obat)

  • VenlafaksinSNRIModerat

    Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (label Venlafaksin, Interaksi obat)

  • ZiprasidonantipsikotikModerat

    Ziprasidone should be used with particular caution in patients with known cardiovascular disease (history of myocardial infarction or ischemic heart disease, heart failure or conduction abnormalities), cerebrovascular disease, or conditions which would predispose patients to hypotension (dehydration, hypovolemia, and treatment with antihypertensive medications). (label Ziprasidon, Peringatan dan perhatian)

Penyebutan minor (21)

  • ButorfanolopioidMinor

    In such cases, butorphanol should be discontinued and the hypertension treated with antihypertensive drugs. (label Butorfanol, Peringatan)

  • Dekstroamfetaminstimulan SSPMinor

    Antihypertensives Amphetamines may antagonize the hypotensive effects of antihypertensives. (label Dekstroamfetamin, Interaksi obat)

  • Desipraminantidepresan trisiklikMinor

    This drug is capable of blocking the antihypertensive effect of guanethidine and similarly acting compounds. (label Desipramin, Peringatan)

  • Desogestrel dan etinilestradiolkontrasepsi oralMinor

    If other contraceptive methods are not suitable, hormonal contraceptive therapy may continue combined with antihypertensive therapy. (label Desogestrel dan etinilestradiol, Peringatan)

  • EfedrinsimpatomimetikMinor

    Examples: α-adrenergic antagonists, β-adrenergic receptor antagonists, reserpine, quinidine, mephentermine Other Drug Interactions G u anethidine C linical Impact: Ephedrine may inhibit the neuron blockage produced by guanethidine, resulting in loss of antihypertensive effectiveness. (label Efedrin, Interaksi obat)

  • HidralazinvasodilatorMinor

    When other potent parenteral antihypertensive drugs, such as diazoxide, are used in combination with hydralazine, patients should be continuously observed for several hours for any excessive fall in blood pressure. (label Hidralazin, Interaksi obat)

  • ACE Inhibitors FIRAZYR is a bradykinin B2 receptor antagonist and thereby has the potential to have a pharmacodynamic interaction with ACE inhibitors where FIRAZYR may attenuate the antihypertensive effect of ACE inhibitors. (label Ikatibant, Interaksi obat)

  • Isradipinpenghambat kanal kalsium dihidropiridinMinor

    In a study in hypertensive patients, addition of isradipine to existing hydrochlorothiazide therapy did not result in any unexpected adverse effects, and isradipine had an additional antihypertensive effect. (label Isradipin, Interaksi obat)

  • Kalium kloridasuplemen kaliumMinor

    Renin-angiotensin-aldosterone Inhibitors Drugs that inhibit the renin-angiotensin-aldosterone system (RAAS) including angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), spironolactone, eplerenone, or aliskiren produce potassium retention by inhibiting aldosterone production. (label Kalium klorida, Interaksi obat)

  • Kalium sitratsuplemen kaliumMinor

    Renin-Angiotensin-Aldosterone System Inhibitors 7.3 Renin-Angiotensin-Aldosterone System Inhibitors Drugs that inhibit the renin-angiotensin-aldosterone system (RAAS) including angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), spironolactone, eplerenone, or aliskiren produce potassium retention by inhibiting aldosterone production. (label Kalium sitrat, Interaksi obat)

  • KlorpromazinantipsikotikMinor

    Chlorpromazine may counteract the antihypertensive effect of guanethidine and related compounds. (label Klorpromazin, Peringatan)

  • MeksiletinantiaritmiaMinor

    In a large compassionate use program mexiletine has been used concurrently with commonly employed antianginal, antihypertensive, and anticoagulant drugs without observed interactions. (label Meksiletin, Interaksi obat)

  • MetildopaantihipertensiMinor

    Drug Interactions When methyldopa is used with other antihypertensive drugs, potentiation of antihypertensive effect may occur. (label Metildopa, Interaksi obat)

  • Metoprololpenyekat betaMinor

    Because of its relative beta 1 cardio-selectivity, however, Metoprolol Tartrate Tablets may be used in patients with bronchospastic disease who do not respond to, or cannot tolerate, other antihypertensive treatment. (label Metoprolol, Peringatan dan perhatian)

  • Losartan, glipizide and levothyroxine did not show any changes in exposure when co-administered with LOKELMA. (label Natrium zirkonium siklosilikat, Interaksi obat)

  • Nisoldipinpenghambat kanal kalsium dihidropiridinMinor

    The blood pressure effect of SULAR tended to be greater in patients on atenolol than in patients on no other antihypertensive therapy. (label Nisoldipin, Interaksi obat)

  • NitroprusidvasodilatorMinor

    Hypertensive patients, and patients concomitantly receiving other antihypertensive medications, may be more sensitive to the effects of sodium nitroprusside than normal subjects. (label Nitroprusid, Peringatan)

  • Nortriptilinantidepresan trisiklikMinor

    The antihypertensive action of guanethidine and similar agents may be blocked. (label Nortriptilin, Peringatan)

  • ProklorperazinantipsikotikMinor

    Antihypertensive effects of guanethidine and related compounds may be counteracted when phenothiazines are used concomitantly. (label Proklorperazin, Perhatian)

  • Protriptilinantidepresan trisiklikMinor

    Protriptyline may block the antihypertensive effect of guanethidine or similarly acting compounds. (label Protriptilin, Peringatan)

  • TrifluoperazinantipsikotikMinor

    Antihypertensive effects of guanethidine and related compounds may be counteracted when phenothiazines are used concurrently. (label Trifluoperazin, Perhatian)

Tidak ada interaksi bermakna yang dilaporkan (7)

  • Digoksinglikosida digitalisTanpa interaksi

    Drug Interactions No clinically significant drug interactions have been found in studies of losartan potassium with hydrochlorothiazide, digoxin, warfarin, cimetidine and phenobarbital. (label Losartan, Interaksi obat)

  • Eritromisinantibiotik makrolidaTanpa interaksi

    The AUC of active metabolite following oral losartan was not affected by erythromycin, an inhibitor of P450 3A4, but the AUC of losartan was increased by 30%. (label Losartan, Interaksi obat)

  • FenobarbitalbarbituratTanpa interaksi

    Drug Interactions No clinically significant drug interactions have been found in studies of losartan potassium with hydrochlorothiazide, digoxin, warfarin, cimetidine and phenobarbital. (label Losartan, Interaksi obat)

  • Drug Interactions No clinically significant drug interactions have been found in studies of losartan potassium with hydrochlorothiazide, digoxin, warfarin, cimetidine and phenobarbital. (label Losartan, Interaksi obat)

  • Ketokonazolantijamur azolTanpa interaksi

    Conversion of losartan to its active metabolite after intravenous administration is not affected by ketoconazole, an inhibitor of P450 3A4. (label Losartan, Interaksi obat)

  • Simetidinpenghambat H2Tanpa interaksi

    Drug Interactions No clinically significant drug interactions have been found in studies of losartan potassium with hydrochlorothiazide, digoxin, warfarin, cimetidine and phenobarbital. (label Losartan, Interaksi obat)

  • WarfarinantikoagulanTanpa interaksi

    Drug Interactions No clinically significant drug interactions have been found in studies of losartan potassium with hydrochlorothiazide, digoxin, warfarin, cimetidine and phenobarbital. (label Losartan, Interaksi obat)

Periksa Losartan terhadap semua yang Anda gunakan. Tambahkan seluruh daftar Anda; setiap pasangan diperiksa sekaligus.

Buka di pemeriksa

Bukan nasihat medis. Tingkat keparahan mencerminkan kata-kata dalam label, bukan keadaan Anda. Tanda “mayor” bisa merupakan hal yang rutin di bawah pengawasan, dan tanda “minor” bisa menjadi penting pada dosis tinggi. Tanyakan kepada apoteker.